Phase I Study of Capecitabine, Oxaliplatin, Bevacizumab, and Everolimus in Advanced Solid Tumors

PURPOSE: To define maximum tolerated dose (MTD), toxicities, and pharmacodynamics of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumor patients. DESIGN: This was a standard “3+3” dose-escalation trial. All subjects received bevacizumab 7.5mg/kg on day one of each cycle....

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Rangwala, F., Bendell, J., Kozloff, M., Arrowood, C., Dellinger, A., Meadows, J., Tourt-Uhlig, S., Murphy, J., Meadows, K.L., Starr, A., Broderick, S., Brady, J.C., Cushman, S. M., Morse, M., Uronis, H., Hsu, S.D., Zafar, S.Y., Wallace, J., Starodub, A., Strickler, J., Pang, H., Nixon, A.B., Hurwitz, H.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4103954/
https://ncbi.nlm.nih.gov/pubmed/24711126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0089-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares